SCHEMBL3192305

SCHEMBL3192305

Cc1cc(=O)c(C(=O)c2ccc(Cl)cc2)c(C)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 4/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
SRD5A2 P31213 1/20 0.42
MAPK1 P28482 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13531552 0.87 ALDH1A1 (0.50) NPSR1HPGDLMNANPC1RAB9A
SCHEMBL4711599 0.86 NPC1 (0.40) NPSR1HPGDLMNACYP1A2GAA
SCHEMBL3175489 0.83 ALDH1A1 (0.43) HPGDLMNACYP1A2GAANPC1
SCHEMBL10392166 0.79 RAB9A (0.56) GAANPC1RAB9AKMT2AMEN1
SCHEMBL10686284 0.73 NOTUM (0.45) HPGDCYP1A2GAASMN1; SMN2ALDH1A1
SCHEMBL3188766 0.73 CYP1A2 (0.45) HPGDCYP1A2GAANPC1RAB9A
SCHEMBL9454351 0.72 CCNC (0.37) HPGDCYP1A2GAAMAPTALDH1A1
SCHEMBL9269940 0.71 SLC2A1 (0.49) HPGDLMNACYP1A2GAANPC1
SCHEMBL3186815 0.71 ADORA1 (0.47) NPSR1HPGDLMNAGAANPC1
SCHEMBL11181578 0.70 PDE4A (0.67) NPSR1HPGDCYP1A2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010035-A1 Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors TORRENT PHARMACEUTICALS LTD. (IN) 2010-01-14 US disclosed
EP-1996588-A1 NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS Torrent Pharmaceuticals Ltd (IN) 2008-12-03 EP disclosed
WO-2007100295-A1 NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS TORRENT PHARMACEUTICALS LTD (IN) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010035-A1 Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors EDNRA, EDNRB, AGTR1 NPSR1 142/4885HPGD 2587/4885LMNA 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.